Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 72, Issue -, Pages 104-110Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-203037
Keywords
-
Categories
Funding
- National Institute for Health Research (NIHR) Biomedical Research Centre
- King's College London
- EuFP7 programme MAARS (Microbes in Allergy and Autoimmunity Related to the Skin)
- Medical Research Council [MR/J006742/1] Funding Source: researchfish
Ask authors/readers for more resources
Psoriasis is a common immune-mediated disease of the skin, which associates in 20-30% of patients with psoriatic arthritis (PsA). The immunopathogenesis of both conditions is not fully understood as it is the result of a complex interaction between genetic, environmental and immunological factors. At present there is no cure for psoriasis and there are no specific markers that can accurately predict disease progression and therapeutic response. Therefore, biomarkers for disease prognosis and response to treatment are urgently needed to help clinicians with objective indications to improve patient management and outcomes. Although many efforts have been made to identify psoriasis/PsA biomarkers none of them has yet been translated into routine clinical practice. In this review we summarise the different classes of possible biomarkers explored in psoriasis and PsA so far and discuss novel strategies for biomarker discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available